Get the Stockscreener App
1.31
0.00%
0.00
Nextcure Inc stock is traded at $1.31, with a volume of 3,404.
It is up +0.00% in the last 24 hours and down -2.96% over the past month.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
See More
Previous Close:
$1.31
Open:
$1.3477
24h Volume:
3,404
Relative Volume:
0.10
Market Cap:
$36.65M
Revenue:
-
Net Income/Loss:
$-61.28M
P/E Ratio:
-0.5198
EPS:
-2.52
Net Cash Flow:
$-46.46M
1W Performance:
-6.43%
1M Performance:
-2.96%
6M Performance:
-14.38%
1Y Performance:
+11.02%
1-Day Range:
$1.30
$1.3477
1-Week Range:
$1.30
$1.43
52-Week Range:
$1.03
$2.57
Nextcure Inc Stock (NXTC) Company Profile
Name
Nextcure Inc
Sector
Industry
Phone
240-399-4900
Address
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-22 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| Mar-05-21 | Upgrade | Truist | Hold → Buy |
| Jan-15-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-16-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Jul-13-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-13-20 | Downgrade | SunTrust | Buy → Hold |
| Jun-01-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-01-20 | Downgrade | The Benchmark Company | Buy → Hold |
| May-26-20 | Initiated | JMP Securities | Mkt Outperform |
| Mar-24-20 | Initiated | The Benchmark Company | Buy |
| Mar-02-20 | Initiated | ROTH Capital | Buy |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Dec-05-19 | Initiated | Needham | Buy |
| Nov-26-19 | Initiated | BTIG Research | Buy |
| Jul-09-19 | Initiated | BofA/Merrill | Buy |
| Jun-03-19 | Initiated | Morgan Stanley | Overweight |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Nextcure Inc Stock (NXTC) Latest News
NextCure (NASDAQ:NXTC) Shares Down 3.6% – Here’s Why - Defense World
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting - The Manila Times
Elevation Capital Advisory LLC Purchases New Shares in Vanguard Information Technology ETF (NYSEARCA:VGT) - americanbankingnews.com
Affinity Asset Advisors LLC Invests $432,000 in NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) - Defense World
NextCure, Inc. (NASDAQ:NXTC) Shares Purchased by Logos Global Management LP - Defense World
Next plc Executes Share Buyback Program - TipRanks
Nexteq PLC Announces Share Buyback and Voting Rights Update - TipRanks
Next PLC Executes Share Buy-Back for Cancellation - TipRanks
Next plc Conducts Share Buyback and Cancellation - TipRanks
Next lifts profit guidance to almost £1bn - Investors Chronicle
Next PLC’s Fresh Guidance Lift, Overseas Plans Boost Shares - The Wall Street Journal
Next PLC Impresses Investors with Yet Another Guidance Upgrade - TipRanks
Next is approaching a historic profit landmark- what is driving this growth? - Proactive Investors Australia
Next Shares Rise 3% As Full-Year Estimates Hiked - Forbes
Next shares rise on upbeat full-year profit outlook By Investing.com - Investing.com South Africa
Record high for Next shares after guidance raised again - Interactive Investor
Next Lifts Profit Target Again as Autumn Fashion Sales Surge - BNN Bloomberg
UK's Next raises forecast to put 1 billion pound profit in sight - Reuters
Britain's Next on track for 1 billion pounds annual profit - Marketscreener.com
Next Raises FY Pre-Tax Profit Guidance By £15 Mln - XM
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 - ForexTV.com
Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Assenagon Asset Management S.A. Sells 864 Shares of Stantec Inc. (NYSE:STN) - Defense World
Assenagon Asset Management S.A. Buys 131 Shares of Watsco, Inc. (NYSE:WSO) - Defense World
Assenagon Asset Management S.A. Sells 473,491 Shares of U.S. Silica Holdings, Inc. (NYSE:SLCA) - Defense World
Vanguard Group Inc. Raises Stock Holdings in NextCure, Inc. (NASDAQ:NXTC) - Defense World
NextCure (NASDAQ:NXTC) Stock Rating Reaffirmed by Needham & Company LLC - Defense World
NextCure, Inc. (NASDAQ:NXTC) Sees Significant Drop in Short Interest - Defense World
NextCure (NASDAQ:NXTC) Trading Down 3.6% - Defense World
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate - Simply Wall St
Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui - openPR
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference - Quantisnow
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference - Quantisnow
NextCure to Present at the JMP Securities Life Sciences Conference - Quantisnow
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference - Quantisnow
NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody ... - Quantisnow
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual ... - Quantisnow
NextCure to Present at the Ladenburg Thalmann Healthcare Conference - Quantisnow
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference - Quantisnow
What Type Of Shareholders Own The Most Number of NextCure, Inc. (NASDAQ:NXTC) Shares? - Yahoo Movies Canada
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - ForexTV.com
Chronic Myelomonocytic Leukaemia Pipeline 2024 | Latest Drugs Approvals, FDA, Clinical Trials, and Companies - openPR
Cable Car Capital LLC Makes New Investment in MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Cable Car Capital LLC Purchases New Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Cable Car Capital LLC Buys Shares of 200000 Aimfinity Investment Corp. I (NASDAQ:AIMBU) - Defense World
Cable Car Capital LLC Buys New Holdings in GigCapital5, Inc. (NYSE:GIA) - Defense World
Cable Car Capital LLC Acquires Shares of 25000 A SPAC II Acquisition Corp. (NASDAQ:ASCB) - Defense World
Cable Car Capital LLC Invests $4.67 Million in Cornerstone Total Return Fund, Inc. (NYSEAMERICAN:CRF) - Defense World
Cable Car Capital LLC Acquires Shares of 615878 NextCure, Inc. (NASDAQ:NXTC) - Defense World
Cable Car Capital LLC Takes Position in GEE Group Inc. (NYSE:JOB) - Defense World
Cable Car Capital LLC Buys Shares of 300000 Welsbach Technology Metals Acquisition Corp. (NASDAQ:WTMA) - Defense World
Nextcure Inc Stock (NXTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):